EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY-NC-ND 4.0

Development and validation of an artificial intelligence-based model for predicting teicoplanin plasma concentrations in intensive care unit patients with pulmonary infections: a retrospective study

Qinghua Zhang, Qi Zhang, Banglong Wang, Jianfang Shao, Jing Yu, Jiao Man, Xin Liu, Li Sun, Wenjun Zheng

International Journal of Clinical Pharmacy · 2026

DOI: 10.1007/s11096-026-02095-2 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift International Journal of Clinical Pharmacy, 2026. Verfasst von Qinghua Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Dalian Medical University, 222 Zhongshan Road, DalianLiaoning, 116021, China. Hauptthemen laut MEDLINE: Teicoplanin, Intensive Care Units, Anti-Bacterial Agents, Drug Monitoring. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Teicoplanin is widely used to treat pulmonary infections, particularly in critically ill patients with gram-positive bacterial infections. However, its plasma concentration varies substantially between individuals owing to heterogeneity in renal function, comorbidities, and concomitant medications, leading to subtherapeutic or toxic exposures. Therapeutic drug monitoring (TDM) remains the standard approach for individualized dosing; however, its application in intensive care unit (ICU) is limited by resource and timing constraints. Hence, developing reliable predictive models to estimate teicoplanin plasma concentrations could enhance the precision and efficiency of TDM, and support pharmacist-led dosing decisions. AIM: This study aimed to develop and validate machine learning (ML)-based models to predict the teicoplanin plasma concentration in ICU patients with pulmonary infections using real-world clinical data, thereby advancing personalized antibiotic therapy in clinical pharmacy practice. METHOD: This retrospective cohort study was conducted between June 2018 and September 2023 in ICU patients receiving teicoplanin therapy at a tertiary hospital in China. After the univariate analysis to exclude irrelevant factors, sequential forward selection was performed to identify the optimal feature subset. The dataset was divided into a training set (80%) and a test set (20%), and ten ML algorithms were developed to predict teicoplanin plasma concentrations. Model performance was evaluated by ten-fold cross-validation of the training set and validated using an independent external cohort. RESULTS: A total of 270 eligible patients were included in the training and test sets, and additional 118 patients formed the external validation cohort. Seven variables were identified as the most predictive features: daily dose, diabetes, hemodialysis, imipenem, human serum albumin, urea, and red blood cell count. Among the ten algorithms tested, the TabNet model achieved the best predictive performance on the test set (R2 = 0.88, RMSE = 3.24, MAE = 2.64, MAPE = 17.88%, ± 30% accuracy = 81.54%) and maintained robust external validation (R2 = 0.79, ± 30% accuracy = 85.59%). CONCLUSION: This study developed a TabNet model based on real-world data, which can accurately and interpretably predict the teicoplanin plasma concentration of patients with pulmonary infection in the ICU. The derived online prediction tool provides references for the application of artificial intelligence-assisted precision medicine in antibacterial treatment and the optimization of drug monitoring for ICU patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TeicoplaninIntensive Care UnitsAnti-Bacterial AgentsDrug MonitoringArtificial IntelligenceHumansRetrospective StudiesFemaleMaleMiddle AgedPredictive Learning ModelsAgedMachine Learning

Stichwörter der Autor:innen

Intensive care unitMachine learningPersonalized medicinePlasma concentrationPulmonary infectionTeicoplaninTherapeutic drug monitoring

Substanzen

TeicoplaninAnti-Bacterial Agents

Autor:innen und Institutionen

  • The First Affiliated Hospital of Dalian Medical University, 222 Zhongshan Road, DalianLiaoning, 116021, China.
  • Center Hospital Affiliated With, Dalian University of Technology, Dalian, 116021, Liaoning, China.
  • Dalian Market Supervision Service Center, Dalian, 116021, Liaoning, China.
  • Department of Clinical Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, 050017, China.
  • The Technology Innovation Center for Artificial Intelligence in Clinical Pharmacy of Hebei Province, The First Hospital of Hebei Medical University, Shijiazhuang, 050017, China.
  • The First Affiliated Hospital of Dalian Medical University, 222 Zhongshan Road, DalianLiaoning, 116021, China. zwjxw1985@163.com.

Zitieren

APA

Zhang, Q., Zhang, Q., Wang, B., Shao, J., Yu, J., Man, J., Liu, X., Sun, L., & Zheng, W. (2026). Development and validation of an artificial intelligence-based model for predicting teicoplanin plasma concentrations in intensive care unit patients with pulmonary infections: a retrospective study. International Journal of Clinical Pharmacy. https://doi.org/10.1007/s11096-026-02095-2

Vancouver

Zhang Q, Zhang Q, Wang B, Shao J, Yu J, Man J, et al. Development and validation of an artificial intelligence-based model for predicting teicoplanin plasma concentrations in intensive care unit patients with pulmonary infections: a retrospective study. International Journal of Clinical Pharmacy. 2026. doi:10.1007/s11096-026-02095-2

BibTeX
@article{Zhang2026,
  author = {Zhang, Qinghua and Zhang, Qi and Wang, Banglong and Shao, Jianfang and Yu, Jing and Man, Jiao and Liu, Xin and Sun, Li and Zheng, Wenjun},
  title = {Development and validation of an artificial intelligence-based model for predicting teicoplanin plasma concentrations in intensive care unit patients with pulmonary infections: a retrospective study},
  journal = {International Journal of Clinical Pharmacy},
  year = {2026},
  doi = {10.1007/s11096-026-02095-2}
}
Kostenlos starten →